Losartan
Based on 59 publication(s) in Google Scholar
Losartan is an angiotensin II receptor antagonist, competing with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM.
For research use only. We do not sell to patients.
- Purity: 99.41%
- CAS No.: 114798-26-4
- Formula: C22H23ClN6O
- Molecular Weight:422.91
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) Losartan
More- Nat Commun. 2025 Nov 25;16(1):10430. [Abstract]
- Adv Sci (Weinh). 2024 Dec 5:e2410360. [Abstract]
- J Immunother Cancer. 2026 Mar 25;14(3):e012426. [Abstract]
- J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]
- Mol Biomed. 2025 Feb 11;6(1):10. [Abstract]
- Adv Healthc Mater. 2025 Apr;14(11):e2500176. [Abstract]
- Cell Death Dis. 2020 May 22;11(5):390. [Abstract]
- Phytomedicine. 2024 Dec 3:136:156314. [Abstract]
- Phytomedicine. 2023 Apr:112:154700. [Abstract]
- Phytomedicine. 2022 Mar 21;100:154067. [Abstract]
- Apoptosis. 2024 Oct;29(9-10):1499-1514. [Abstract]
- Clin Sci. 2021 Mar 26;135(6):793-810. [Abstract]
- J Transl Med. 2024 Jan 5;22(1):26. [Abstract]
- Oncogene. 2023 Apr;42(15):1166-1180. [Abstract]
- Cell Rep. 2026 May 28;45(6):117471.
- Clin Transl Med. 2025 Jun;15(6):e70361. [Abstract]
- Clin Transl Med. 2023 Mar;13(3):e1213. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- Antioxidants (Basel). 2024 Aug 7;13(8):958. [Abstract]
- Int J Nanomedicine. 2018 Nov 13:13:7409-7426. [Abstract]
- Cell Mol Life Sci. 2025 Nov 13;82(1):396. [Abstract]
- Colloids Surf B Biointerfaces. 2025 Nov 25:259:115314. [Abstract]
- Chem Biol Interact. 2023 Sep 1:382:110636. [Abstract]
- Int J Mol Sci. 2023 Feb 3;24(3):2960. [Abstract]
- Biomolecules. 2023 Apr 25;13(5):740. [Abstract]
- Biomolecules. 2022 Nov 25;12(12):1754. [Abstract]
- Eur J Pharmacol. 2025 Dec 15:1009:178390. [Abstract]
- Int Immunopharmacol. 2025 Sep 23:162:115168. [Abstract]
- J Mol Cell Cardiol. 2025 May:202:133-143. [Abstract]
- Int Immunopharmacol. 2024 Jul 19:139:112707. [Abstract]
- Int Immunopharmacol. 2023 Oct:123:110761. [Abstract]
- J Physiol. 2024 Jan;602(2):317-332. [Abstract]
- FASEB J. 2025 Jul 15;39(13):e70761. [Abstract]
- FASEB J. 2019 May;33(5):6254-6268. [Abstract]
- FASEB J. 2018 Sep;32(9):5051-5062. [Abstract]
- Am J Physiol Heart Circ Physiol. 2018 Mar 1;314(3):H580-H592. [Abstract]
- Sci Rep. 2019 Dec 19;9(1):19450. [Abstract]
- Toxicol Appl Pharmacol. 2026 Mar 27:511:117802. [Abstract]
- Toxicol Appl Pharmacol. 2024 May:486:116945. [Abstract]
- Front Physiol. 2020 Sep 8;11:560170. [Abstract]
- Am J Physiol Renal Physiol. 2020 Nov 1;319(5):F941-F953. [Abstract]
- Kaohsiung J Med Sci. 2025 Nov 28:e70144. [Abstract]
- Toxicol Lett. 2025 Apr:406:31-37. [Abstract]
- J Pharmacol Sci. 2020 Sep;144(1):30-42. [Abstract]
- J Appl Toxicol. 2026 Jun 17. [Abstract]
- J Orthop Surg Res. 2024 Feb 19;19(1):147. [Abstract]
- Nefrologia. 2023 Sep 6.
- Gene. 2022 Apr 30:820:146239. [Abstract]
- Biochem Biophys Res Commun. 2025 Jan:745:151256. [Abstract]
- Rep Biochem Mol Biol. 2021 Jul;10(2):314-326. [Abstract]
- Arch Biol Sci. 2021 Jun.
- bioRxiv. 2026 Jun 19.
- bioRxiv. 2026 Jun 8:2026.06.03.729868. [Abstract]
- bioRxiv. 2026 Apr 7.
- SSRN. 2025 Nov 6.
- Res Sq. 2024 Jul 16.
- Friedrich-Alexander University Erlangen-Nuremberg. 2023 May 2.
- Research Square Print. September 13th, 2022.
- Oxid Med Cell Longev. 2022 Feb 18:2022:5044046. [Abstract]
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
Cell Proliferation/Viability Assay
-
Apoptosis Analysis
All Angiotensin Receptor Isoforms
More
Biological Activity
|
AT1 Receptor |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
40 nM
Compound: DuP-753
|
In vitro inhibitory activity against rat Angiotensin II receptor, type 1 expressed in CHO cells
In vitro inhibitory activity against rat Angiotensin II receptor, type 1 expressed in CHO cells
|
[PMID: 10579816] |
| CHO-K1 | IC50 |
28.6 nM
Compound: Losartan
|
Displacement of [125I]Sar1Ile8-Ang2 from human AT1 receptor expressed in CHO-K1 cell membranes after 180 mins
Displacement of [125I]Sar1Ile8-Ang2 from human AT1 receptor expressed in CHO-K1 cell membranes after 180 mins
|
[PMID: 26397395] |
| COS-7 | IC50 |
12.1 nM
Compound: Cozaar
|
Displacement of 125I-[Sar1,Leu8] angiotensin-2 from rat type 1 angiotensin-2 receptor expressed in African green monkey COS7 cells after 24 hrs
Displacement of 125I-[Sar1,Leu8] angiotensin-2 from rat type 1 angiotensin-2 receptor expressed in African green monkey COS7 cells after 24 hrs
|
[PMID: 26810314] |
| HASMC | IC50 |
0.71 nM
Compound: Losartan DuP-753
|
Inhibitory activity against Ang II-induced proliferation of human aortic smooth muscle cells in a dose dependent manner
Inhibitory activity against Ang II-induced proliferation of human aortic smooth muscle cells in a dose dependent manner
|
[PMID: 8576904] |
| HEK293 | IC50 |
>250 μM
Compound: losartan
|
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay
|
[PMID: 23241029] |
| HEK293 | IC50 |
6 nM
Compound: losartan
|
Displacement of 125[I-Sar1-Ile8]ANG II from human AT1 receptor expressed in HEK293 membranes after 1 hr by gamma counting
Displacement of 125[I-Sar1-Ile8]ANG II from human AT1 receptor expressed in HEK293 membranes after 1 hr by gamma counting
|
[PMID: 22889560] |
| HEK-293T | IC50 |
2.4 μg/mL
Compound: losartan
|
Antagonist activity at HA-tagged mouse AT1a angiotensin 2 receptor expressed in HEK293T cells assessed as decrease in angiotensin 2-induced intracellular calcium uptake
Antagonist activity at HA-tagged mouse AT1a angiotensin 2 receptor expressed in HEK293T cells assessed as decrease in angiotensin 2-induced intracellular calcium uptake
|
[PMID: 18672373] |
Losartan competes with the binding of angiotensin II to AT1 receptors. The concentration that inhibits 50% of the binding of angiotensin II (IC50) is 20 nM[1]. Losartan (40 μM) affects ISC but prevents the effect of ANGII on ISC[2]. Losartan significantly reduces Ang II-mediated cell proliferation in endometrial cancer cells. The combination of losartan and anti-miR-155 has a significantly greater antiproliferative effect compared to each drug alone[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 114798-26-4
-
Appearance Solid
-
Molecular Weight 422.91
-
Formula C22H23ClN6O
-
Color White to light yellow
-
SMILES
OCC1=C(Cl)N=C(CCCC)N1CC2=CC=C(C3=CC=CC=C3C4=NNN=N4)C=C2
-
Synonyms
DuP-753
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (59)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
FGF4-FGFR1 signaling promotes podocyte survival and glomerular function to ameliorate diabetic kidney disease in male mice. [Abstract]2025 Nov 25;16(1):10430. PMID: 41290710
Losartan purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 25;16(1):10430. [Abstract]
Blood glucose levels were significantly reduced in EMP-treated mice but remained unchanged with Losartan potassium (LOS, oral, 10 mg/kg/day) treatment.
-
Adv Sci (Weinh)
Targeted SPP1 Inhibition of Tumor-Associated Myeloid Cells Effectively Decreases Tumor Sizes. [Abstract]2024 Dec 5:e2410360. PMID: 39639496 -
J Immunother Cancer
Telmisartan increases olaparib efficacy in homologous recombination proficient tumors by augmenting type I interferon production. [Abstract]2026 Mar 25;14(3):e012426. PMID: 41881499 -
J Immunother Cancer
Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade. [Abstract]2024 Sep 6;12(9):e009327. PMID: 39244215
Losartan purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]
Proliferation ability of MDA-MB-231 and HS578T cells in control and Losartan (10µM)-treated groups was assessed by colony formation assay.
Losartan purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]
Apoptosis level of MDA-MB-231 and HS578T cells in control and Losartan (10µM)-treated groups was assessed by flow cytometry assay.
Losartan purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]
Migration ability of MDA-MB-231 and HS578T cells in control and Losartan (10µM)-treated groups were assessed by Boyden chamber assay.
Losartan purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]
Expression of COL1A1 in control and Losartan (10µM)-treated CAFs was assessed by qPCR and Western blotting assays.
Losartan purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2024 Sep 6;12(9):e009327. [Abstract]
Expression of COL1A1 in control and Losartan (10µM)-treated CAFs was assessed by immunofluorescence assay.
-
Mol Biomed
2025 Feb 11;6(1):10. PMID: 39932642 -
Adv Healthc Mater
Cascade-Responsive Nanoprodrug Disrupts Immune-Fibroblast Communications for Potentiated Cancer Mechanoimmunotherapy. [Abstract]2025 Apr;14(11):e2500176. PMID: 40079115 -
Cell Death Dis
Sodium-glucose cotransporter 2 inhibition suppresses HIF-1α-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice. [Abstract]2020 May 22;11(5):390. PMID: 32444604
Losartan purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 May 22;11(5):390. [Abstract]
Both dapagliflozin and Losartan potassium treatment significantly reduced the urinary albumin levels at 12 weeks.
Losartan purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 May 22;11(5):390. [Abstract]
Both dapagliflozin and Losartan potassium treatment significantly reduced the NGAL levels at 12 weeks.
Losartan purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2020 May 22;11(5):390. [Abstract]
Morphological analysis revealed that glomerular tuft area , mesangial expansion, and mesangial matrix hyperplasia (fractional mesangial area, FMA), which were increased in diabetic mice, were also equally improved by dapagliflozin and Losartan potassium treatment.
-
Phytomedicine
Phillygenin improves diabetic nephropathy by inhibiting inflammation and apoptosis via regulating TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling pathways. [Abstract]2024 Dec 3:136:156314. PMID: 39647467
Losartan purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Dec 3:136:156314. [Abstract]
The CCK-8 assay was performed to determine cell viability after Losartan potassium treatment under HG conditions for 48 h.
Losartan purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Dec 3:136:156314. [Abstract]
The kidney/body weight ratios demonstrated that both Losartan potassium and PHI exerted nephroprotective effects against DN, with H-PHI treatment exhibiting a greater effect.
-
Phytomedicine
Rutin alleviates EndMT by restoring autophagy through inhibiting HDAC1 via PI3K/AKT/mTOR pathway in diabetic kidney disease. [Abstract]2023 Apr:112:154700. PMID: 36774842 -
Phytomedicine
2022 Mar 21;100:154067. PMID: 35349832 -
Apoptosis
Targeting PAX8 sensitizes ovarian cancer cells to ferroptosis by inhibiting glutathione synthesis. [Abstract]2024 Oct;29(9-10):1499-1514. PMID: 38853202 -
Clin Sci
Soluble (pro)renin receptor induces endothelial dysfunction and hypertension in mice with diet-induced obesity via activation of angiotensin II type 1 receptor. [Abstract]2021 Mar 26;135(6):793-810. PMID: 33625485 -
J Transl Med
(Pro)renin receptor mediates tubular epithelial cell pyroptosis in diabetic kidney disease via DPP4-JNK pathway. [Abstract]2024 Jan 5;22(1):26. PMID: 38183100 -
Oncogene
Stromal nicotinamide N-methyltransferase orchestrates the crosstalk between fibroblasts and tumour cells in oral squamous cell carcinoma: evidence from patient-derived assembled organoids. [Abstract]2023 Apr;42(15):1166-1180. PMID: 36823377 -
-
Clin Transl Med
DDR2-mediated autophagy inhibition contributes to angiotensin II-induced adventitial remodeling. [Abstract]2025 Jun;15(6):e70361. PMID: 40468620 -
Clin Transl Med
Angiotensin receptor blockers retard the progression and fibrosis via inhibiting the viability of AGTR1+ CAFs in intrahepatic cholangiocarcinoma. [Abstract]2023 Mar;13(3):e1213. PMID: 36855786 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Antioxidants (Basel)
Identification and Validation of the miR/RAS/RUNX2 Autophagy Regulatory Network in AngII-Induced Hypertensive Nephropathy in MPC5 Cells Treated with Hydrogen Sulfide Donors. [Abstract]2024 Aug 7;13(8):958. PMID: 39199205 -
Int J Nanomedicine
Peritumoral implantation of hydrogel-containing nanoparticles and losartan for enhanced nanoparticle penetration and antitumor effect. [Abstract]2018 Nov 13:13:7409-7426. PMID: 30519023 -
Cell Mol Life Sci
Rab26 promotes hypoxia-induced hyperproliferation of PASMCs by modulating the AT1R-STAT3-YAP axis. [Abstract]2025 Nov 13;82(1):396. PMID: 41231254 -
Colloids Surf B Biointerfaces
A losartan-laden thermosensitive hydrogel scaffold to boost tumor chemo-immunotherapy via remodeling tumor mechanical microenvironment. [Abstract]2025 Nov 25:259:115314. PMID: 41319609 -
Chem Biol Interact
Inhibition of AT1R/IP3/IP3R-mediated Ca2+ release protects against calcium oxalate crystals-induced renal oxidative stress. [Abstract]2023 Sep 1:382:110636. PMID: 37454925 -
Int J Mol Sci
2023 Feb 3;24(3):2960. PMID: 36769281 -
Biomolecules
Trametinib-Induced Epidermal Thinning Accelerates a Mouse Model of Junctional Epidermolysis Bullosa. [Abstract]2023 Apr 25;13(5):740. PMID: 37238610 -
Biomolecules
Structure-Based Virtual Screening and Functional Validation of Potential Hit Molecules Targeting the SARS-CoV-2 Main Protease. [Abstract]2022 Nov 25;12(12):1754. PMID: 36551182 -
Eur J Pharmacol
Angiotensin II-induced fibrosis is mediated by activation of FGFR1 pathway in renal epithelial cells: Attenuation by chimeric peptide. [Abstract]2025 Dec 15:1009:178390. PMID: 41274591 -
Int Immunopharmacol
ADAM17 knockdown is more effective than AT1R blocker in alleviating diabetic cardiomyopathy through downregulating the RhoA-ROCK1 pathway. [Abstract]2025 Sep 23:162:115168. PMID: 40633210 -
J Mol Cell Cardiol
Elevated KCa3.1 expression by angiotensin II via the ERK/NF-κB pathway contributes to atrial fibrosis. [Abstract]2025 May:202:133-143. PMID: 40122157 -
Int Immunopharmacol
Anti-tumor effects of telmisartan in glioma-astrocyte non-contact co-cultures: A critical role of astrocytic IL-6-mediated paracrine growth promotion. [Abstract]2024 Jul 19:139:112707. PMID: 39032472 -
Int Immunopharmacol
Telmisartan inhibits microglia-induced neurotoxic A1 astrocyte conversion via PPARγ-mediated NF-κB/p65 degradation. [Abstract]2023 Oct:123:110761. PMID: 37544025 -
J Physiol
miR-22-3p in the rostral ventrolateral medulla promotes hypertension through inhibiting β-arrestin-1. [Abstract]2024 Jan;602(2):317-332. PMID: 38152023 -
FASEB J
Mitochondrial Calcium Uniporter-Mediated Regulation of the SIRT3/GSK3β/β-Catenin Signaling Pathway in Vascular Remodeling. [Abstract]2025 Jul 15;39(13):e70761. PMID: 40622073 -
FASEB J
Transactivation domain of Krüppel-like factor 15 negatively regulates angiotensin II-induced adventitial inflammation and fibrosis. [Abstract]2019 May;33(5):6254-6268. PMID: 30776250 -
FASEB J
Angiotensin II increases angiogenesis by NF-κB-mediated transcriptional activation of angiogenic factor AGGF1. [Abstract]2018 Sep;32(9):5051-5062. PMID: 29641288
Losartan purchased from MedChemExpress. Usage Cited in: FASEB J. 2018 Sep;32(9):5051-5062. [Abstract]
HUVECs are starved for 12 h, treated with 10 mg/mL (9.56 μM) of AngII with or without Losartan or PD123319 for 12 h, and are subsequently used for Western blot analysis.
-
Am J Physiol Heart Circ Physiol
Overexpression of the neuronal human (pro)renin receptor mediates angiotensin II-independent blood pressure regulation in the central nervous system. [Abstract]2018 Mar 1;314(3):H580-H592. PMID: 29350998 -
Sci Rep
AT1 and AT2 receptors modulate renal tubular cell necroptosis in angiotensin II-infused renal injury mice. [Abstract]2019 Dec 19;9(1):19450. PMID: 31857626 -
Toxicol Appl Pharmacol
Saikosaponin D protects against isoproterenol-induced kidney injury in rats by regulating the intrarenal renin-angiotensin system. [Abstract]2026 Mar 27:511:117802. PMID: 41903810 -
Toxicol Appl Pharmacol
In silico and in vitro assessment of drugs potentially causing adverse effects by inhibiting CYP17A1. [Abstract]2024 May:486:116945. PMID: 38688424 -
Front Physiol
Angiotensin II Stimulates the Proliferation and Migration of Lymphatic Endothelial Cells Through Angiotensin Type 1 Receptors. [Abstract]2020 Sep 8;11:560170. PMID: 33013481 -
Am J Physiol Renal Physiol
Soluble (pro)renin receptor promotes the fibrotic response in renal proximal tubule epithelial cells in vitro via the Akt/β-catenin/Snail signaling pathway. [Abstract]2020 Nov 1;319(5):F941-F953. PMID: 32865015 -
Kaohsiung J Med Sci
Forsythiaside A Alleviates Kidney Injury and Intestinal Epithelium Dysfunction in IgA Nephropathy by Inhibiting TLR4/NF-κB Signaling. [Abstract]2025 Nov 28:e70144. PMID: 41313694 -
Toxicol Lett
Discovery of non-steroidal aldo-keto reductase 1D1 inhibitors through automated screening and in vitro evaluation. [Abstract]2025 Apr:406:31-37. PMID: 39988211 -
J Pharmacol Sci
Sustained increased CaMKII phosphorylation is involved in the impaired regression of isoproterenol-induced cardiac hypertrophy in rats. [Abstract]2020 Sep;144(1):30-42. PMID: 32665128 -
J Appl Toxicol
The Angiotensin II Receptor Antagonist Losartan Impairs Female Fertility in Rats: Potential Mediating Role of microRNA-129-1-3p. [Abstract]2026 Jun 17. PMID: 42310910 -
J Orthop Surg Res
Several first-line anti-hypertensives act on fibrosarcoma progression and PD1ab blockade therapy. [Abstract]2024 Feb 19;19(1):147. PMID: 38373964 -
-
Gene
Calcitriol ameliorates renal injury with high-salt diet-induced hypertension by upregulating GLIS2 expression and AMPK/mTOR-regulated autophagy. [Abstract]2022 Apr 30:820:146239. PMID: 35114278 -
Biochem Biophys Res Commun
2025 Jan:745:151256. PMID: 39740402 -
Rep Biochem Mol Biol
Signaling Pathway in the Osmotic Resistance Induced by Angiotensin II AT2 Receptor Activation in Human Erythrocytes. [Abstract]2021 Jul;10(2):314-326. PMID: 34604421 -
-
-
bioRxiv
Angiotensin AT1 Receptors Promote Age-Dependent Expansion of Presympathetic Networks in Spontaneously Hypertensive Rats. [Abstract]2026 Jun 8:2026.06.03.729868. PMID: 42327208 -
-
-
-
-
-
Oxid Med Cell Longev
Angiotensin II Induces Cardiac Edema and Hypertrophic Remodeling through Lymphatic-Dependent Mechanisms. [Abstract]2022 Feb 18:2022:5044046. PMID: 35222798
Solvent & Solubility
DMSO : ≥ 100 mg/mL (236.46 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.92 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
An MTT assay is used to measure cell proliferation and viability. For the assay, 5000 cells in 200 μL media per well are seeded in a 96 well plate. After overnight incubation to allow for cell attachment, the medium is removed by suction. MTT at 1 mg/mL concentration in serum-free medium is added and then incubated for 4 h at 37°C. After removal of MTT solution, 100 μL of DMSO is added to dissolve formazan crystals. Absorbance at 570 nm and at 600 nm as a reference is then measured using a microplate reader. The difference in absorbance is thus relative to the extent of cell survival.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Female Fbn1C1039G/+ mice undergo timed matings with wild-type male mice. At 14.5d post-coitum, pregnant female Fbn1C1039G/+ mice are treated with oral losartan (0.6 g/L in drinking water; n=10), propranolol (0.5 g/L; n=6) or placebo (n=12). Therapy is continued throughout lactation and after weaning until 10 months of age. Mice are sacrificed and examined using the techniques described above. Propranolol is used for comparison with losartan because β-adrenergic receptor blockade is the current albeit controversial standard of care to modulate abnormal growth of the aortic root in MFS. Beginning at 7 weeks of age, wild-type and Fbn1C1039G/+ mice are treated with oral losartan (0.6 g/L in drinking water; n=5), propranolol (0.5 g/L; n=7) or placebo (n=10). Mice are continued on oral therapy for 6 months and then sacrificed.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Burnier, M. Angiotensin II type 1 receptor blockers. Circulation, 2001. 103(6): p. 904-12. [Content Brief]
[2]. Ashry, O., et al. Evidence for expression and function of angiotensin II receptor type 1 in pulmonary epithelial cells. Respir Physiol Neurobiol, 2014. [Content Brief]
[3]. Choi, C.H., et al. Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecol Oncol, 2012. 126(1): p. 124-31. [Content Brief]
[4]. Habashi, J.P., et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science, 2006. 312(5770): p. 117-21. [Content Brief]
[5]. Campbell, D.J., et al. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol, 1995. 26(2): p. 233-40. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3646 mL | 11.8228 mL | 23.6457 mL | 59.1142 mL |
| 5 mM | 0.4729 mL | 2.3646 mL | 4.7291 mL | 11.8228 mL | |
| 10 mM | 0.2365 mL | 1.1823 mL | 2.3646 mL | 5.9114 mL | |
| 15 mM | 0.1576 mL | 0.7882 mL | 1.5764 mL | 3.9409 mL | |
| 20 mM | 0.1182 mL | 0.5911 mL | 1.1823 mL | 2.9557 mL | |
| 25 mM | 0.0946 mL | 0.4729 mL | 0.9458 mL | 2.3646 mL | |
| 30 mM | 0.0788 mL | 0.3941 mL | 0.7882 mL | 1.9705 mL | |
| 40 mM | 0.0591 mL | 0.2956 mL | 0.5911 mL | 1.4779 mL | |
| 50 mM | 0.0473 mL | 0.2365 mL | 0.4729 mL | 1.1823 mL | |
| 60 mM | 0.0394 mL | 0.1970 mL | 0.3941 mL | 0.9852 mL | |
| 80 mM | 0.0296 mL | 0.1478 mL | 0.2956 mL | 0.7389 mL | |
| 100 mM | 0.0236 mL | 0.1182 mL | 0.2365 mL | 0.5911 mL |